FDA Inspection 1219529 — Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd.
The FDA completed an inspection of Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd. on September 8, 2023 in Xuzhou. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- September 8, 2023
- Fiscal Year
- 2023
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Xuzhou (China)